ID   PDPK1_HUMAN             Reviewed;         556 AA.
AC   O15530; H0Y4Z0; Q59EH6; Q6FI20; Q8IV52; Q9BRD5;
DT   18-OCT-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-JAN-1998, sequence version 1.
DT   10-MAY-2017, entry version 197.
DE   RecName: Full=3-phosphoinositide-dependent protein kinase 1;
DE            Short=hPDK1;
DE            EC=2.7.11.1;
GN   Name=PDPK1; Synonyms=PDK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION IN
RP   PHOSPHORYLATION OF PKB/AKT1.
RX   PubMed=9094314; DOI=10.1016/S0960-9822(06)00122-9;
RA   Alessi D.R., James S.R., Downes C.P., Holmes A.B., Gaffney P.R.J.,
RA   Reese C.B., Cohen P.;
RT   "Characterization of a 3-phosphoinositide-dependent protein kinase
RT   which phosphorylates and activates protein kinase B alpha.";
RL   Curr. Biol. 7:261-269(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9368760; DOI=10.1016/S0960-9822(06)00336-8;
RA   Alessi D.R., Deak M., Casamayor A., Caudwell F.B., Morrice N.A.,
RA   Norman D.G., Gaffney P.R.J., Reese C.B., MacDougall C.N., Harbison D.,
RA   Ashworth A., Bownes M.;
RT   "3-phosphoinositide-dependent protein kinase-1 (PDK1): structural and
RT   functional homology with the Drosophila DSTPK61 kinase.";
RL   Curr. Biol. 7:776-789(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Myeloid;
RX   PubMed=9445477; DOI=10.1126/science.279.5351.710;
RA   Stephens L.R., Anderson K.E., Stokoe D., Erdjument-Bromage H.,
RA   Painter G.F., Holmes A.B., Gaffney P.R.J., Reese C.B., McCormick F.,
RA   Tempst P., Coadwell W.J., Hawkins P.T.;
RT   "Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-
RT   trisphosphate-dependent activation of protein kinase B.";
RL   Science 279:710-714(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RT   "Homo sapiens protein coding cDNA.";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 4).
RC   TISSUE=Brain, Kidney, and Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 60-75; 87-100; 184-199; 239-257 AND 284-293,
RP   PHOSPHORYLATION AT SER-241, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RA   Bienvenut W.V., Waridel P., Quadroni M.;
RL   Submitted (MAR-2009) to UniProtKB.
RN   [9]
RP   MUTAGENESIS OF ARG-474, AND ALTERNATIVE SPLICING.
RX   PubMed=9637919; DOI=10.1016/S0960-9822(98)70274-X;
RA   Anderson K.E., Coadwell W.J., Stephens L.R., Hawkins P.T.;
RT   "Translocation of PDK-1 to the plasma membrane is important in
RT   allowing PDK-1 to activate protein kinase B.";
RL   Curr. Biol. 8:684-691(1998).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF PRKCZ.
RX   PubMed=9768361; DOI=10.1016/S0960-9822(98)70444-0;
RA   Chou M.M., Hou W., Johnson J., Graham L.K., Lee M.H., Chen C.S.,
RA   Newton A.C., Schaffhausen B.S., Toker A.;
RT   "Regulation of protein kinase C zeta by PI 3-kinase and PDK-1.";
RL   Curr. Biol. 8:1069-1077(1998).
RN   [11]
RP   FUNCTION IN PHOSPHORYLATION OF PRKACA.
RX   PubMed=9707564; DOI=10.1073/pnas.95.17.9849;
RA   Cheng X., Ma Y., Moore M., Hemmings B.A., Taylor S.S.;
RT   "Phosphorylation and activation of cAMP-dependent protein kinase by
RT   phosphoinositide-dependent protein kinase.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:9849-9854(1998).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF RPS6KB1.
RX   PubMed=9445476; DOI=10.1126/science.279.5351.707;
RA   Pullen N., Dennis P.B., Andjelkovic M., Dufner A., Kozma S.C.,
RA   Hemmings B.A., Thomas G.;
RT   "Phosphorylation and activation of p70s6k by PDK1.";
RL   Science 279:707-710(1998).
RN   [13]
RP   PHOSPHORYLATION AT SER-25; SER-241; SER-393; SER-396 AND SER-410, AND
RP   MUTAGENESIS OF SER-25; SER-241; SER-393; SER-396 AND SER-410.
RX   PubMed=10455013; DOI=10.1042/bj3420287;
RA   Casamayor A., Morrice N.A., Alessi D.R.;
RT   "Phosphorylation of Ser-241 is essential for the activity of 3-
RT   phosphoinositide-dependent protein kinase-1: identification of five
RT   sites of phosphorylation in vivo.";
RL   Biochem. J. 342:287-292(1999).
RN   [14]
RP   MUTAGENESIS OF ALA-277.
RX   PubMed=10364160; DOI=10.1101/gad.13.11.1438;
RA   Paradis S., Ailion M., Toker A., Thomas J.H., Ruvkun G.;
RT   "A PDK1 homolog is necessary and sufficient to transduce AGE-1 PI3
RT   kinase signals that regulate diapause in Caenorhabditis elegans.";
RL   Genes Dev. 13:1438-1452(1999).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF RPS6KA3.
RX   PubMed=10480933; DOI=10.1074/jbc.274.38.27168;
RA   Jensen C.J., Buch M.-B., Krag T.O., Hemmings B.A., Gammeltoft S.,
RA   Froedin M.;
RT   "90-kDa ribosomal S6 kinase is phosphorylated and activated by 3-
RT   phosphoinositide-dependent protein kinase-1.";
RL   J. Biol. Chem. 274:27168-27176(1999).
RN   [16]
RP   FUNCTION IN PHOSPHORYLATION OF PAK1, AND INTERACTION WITH PAK1.
RX   PubMed=10995762; DOI=10.1074/jbc.M006553200;
RA   King C.C., Gardiner E.M., Zenke F.T., Bohl B.P., Newton A.C.,
RA   Hemmings B.A., Bokoch G.M.;
RT   "p21-activated kinase (PAK1) is phosphorylated and activated by 3-
RT   phosphoinositide-dependent kinase-1 (PDK1).";
RL   J. Biol. Chem. 275:41201-41209(2000).
RN   [17]
RP   PHOSPHORYLATION AT TYR-9; SER-241; TYR-373 AND TYR-376, AND
RP   MUTAGENESIS OF TYR-9; TYR-373 AND TYR-376.
RX   PubMed=11481331; DOI=10.1074/jbc.M105916200;
RA   Park J., Hill M.M., Hess D., Brazil D.P., Hofsteenge J.,
RA   Hemmings B.A.;
RT   "Identification of tyrosine phosphorylation sites on 3-
RT   phosphoinositide-dependent protein kinase-1 (PDK1) and their role in
RT   regulating kinase activity.";
RL   J. Biol. Chem. 276:37459-37471(2001).
RN   [18]
RP   ENZYME REGULATION, AND INTERACTION WITH YWHAH AND YWHAQ.
RX   PubMed=12177059; DOI=10.1074/jbc.M205141200;
RA   Sato S., Fujita N., Tsuruo T.;
RT   "Regulation of kinase activity of 3-phosphoinositide-dependent protein
RT   kinase-1 by binding to 14-3-3.";
RL   J. Biol. Chem. 277:39360-39367(2002).
RN   [19]
RP   FUNCTION IN PHOSPHORYLATION OF PKB/AKT1.
RX   PubMed=12167717; DOI=10.1128/MCB.22.17.6247-6260.2002;
RA   Scheid M.P., Marignani P.A., Woodgett J.R.;
RT   "Multiple phosphoinositide 3-kinase-dependent steps in activation of
RT   protein kinase B.";
RL   Mol. Cell. Biol. 22:6247-6260(2002).
RN   [20]
RP   FUNCTION, PHOSPHORYLATION AT TYR-9; TYR-373 AND TYR-376 BY SRC,
RP   INTERACTION WITH PTK2B, AND SUBCELLULAR LOCATION.
RX   PubMed=14585963; DOI=10.1128/MCB.23.22.8019-8029.2003;
RA   Taniyama Y., Weber D.S., Rocic P., Hilenski L., Akers M.L., Park J.,
RA   Hemmings B.A., Alexander R.W., Griendling K.K.;
RT   "Pyk2- and Src-dependent tyrosine phosphorylation of PDK1 regulates
RT   focal adhesions.";
RL   Mol. Cell. Biol. 23:8019-8029(2003).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF SGK3, AND INTERACTION WITH SGK3.
RX   PubMed=14604990; DOI=10.1074/jbc.M309653200;
RA   Nilsen T., Slagsvold T., Skjerpen C.S., Brech A., Stenmark H.,
RA   Olsnes S.;
RT   "Peroxisomal targeting as a tool for assaying protein-protein
RT   interactions in the living cell: cytokine-independent survival kinase
RT   (CISK) binds PDK-1 in vivo in a phosphorylation-dependent manner.";
RL   J. Biol. Chem. 279:4794-4801(2004).
RN   [22]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH GRB14.
RX   PubMed=15210700; DOI=10.1074/jbc.M405340200;
RA   King C.C., Newton A.C.;
RT   "The adaptor protein Grb14 regulates the localization of 3-
RT   phosphoinositide-dependent kinase-1.";
RL   J. Biol. Chem. 279:37518-37527(2004).
RN   [23]
RP   FUNCTION IN PHOSPHORYLATION OF AKT1, AND INTERACTION WITH PKN2.
RX   PubMed=10226025; DOI=10.1016/S0960-9822(99)80186-9;
RA   Balendran A., Casamayor A., Deak M., Paterson A., Gaffney P.,
RA   Currie R., Downes C.P., Alessi D.R.;
RT   "PDK1 acquires PDK2 activity in the presence of a synthetic peptide
RT   derived from the carboxyl terminus of PRK2.";
RL   Curr. Biol. 9:393-404(1999).
RN   [24]
RP   REVIEW ON FUNCTION.
RX   PubMed=15209375; DOI=10.1016/j.semcdb.2003.12.022;
RA   Mora A., Komander D., van Aalten D.M., Alessi D.R.;
RT   "PDK1, the master regulator of AGC kinase signal transduction.";
RL   Semin. Cell Dev. Biol. 15:161-170(2004).
RN   [25]
RP   FUNCTION IN PHOSPHORYLATION OF IKKB, AND INTERACTION WITH IKKB.
RX   PubMed=16207722; DOI=10.1074/jbc.M506235200;
RA   Tanaka H., Fujita N., Tsuruo T.;
RT   "3-Phosphoinositide-dependent protein kinase-1-mediated IkappaB kinase
RT   beta (IkkB) phosphorylation activates NF-kappaB signaling.";
RL   J. Biol. Chem. 280:40965-40973(2005).
RN   [26]
RP   FUNCTION, ENZYME REGULATION, AND INTERACTION WITH STRAP.
RX   PubMed=16251192; DOI=10.1074/jbc.M507539200;
RA   Seong H.A., Jung H., Choi H.S., Kim K.T., Ha H.;
RT   "Regulation of transforming growth factor-beta signaling and PDK1
RT   kinase activity by physical interaction between PDK1 and serine-
RT   threonine kinase receptor-associated protein.";
RL   J. Biol. Chem. 280:42897-42908(2005).
RN   [27]
RP   PHOSPHORYLATION AT SER-396, AND SUBCELLULAR LOCATION.
RX   PubMed=15743829; DOI=10.1128/MCB.25.6.2347-2363.2005;
RA   Scheid M.P., Parsons M., Woodgett J.R.;
RT   "Phosphoinositide-dependent phosphorylation of PDK1 regulates nuclear
RT   translocation.";
RL   Mol. Cell. Biol. 25:2347-2363(2005).
RN   [28]
RP   PHOSPHORYLATION AT TYR-9; TYR-373 AND TYR-376 BY INSR, AND INTERACTION
RP   WITH INSR.
RX   PubMed=16314505; DOI=10.1128/MCB.25.24.10803-10814.2005;
RA   Fiory F., Alberobello A.T., Miele C., Oriente F., Esposito I.,
RA   Corbo V., Ruvo M., Tizzano B., Rasmussen T.E., Gammeltoft S.,
RA   Formisano P., Beguinot F.;
RT   "Tyrosine phosphorylation of phosphoinositide-dependent kinase 1 by
RT   the insulin receptor is necessary for insulin metabolic signaling.";
RL   Mol. Cell. Biol. 25:10803-10814(2005).
RN   [29]
RP   PHOSPHORYLATION AT SER-241 AND THR-513.
RX   PubMed=16780920; DOI=10.1016/j.bioorg.2006.05.002;
RA   Gao X., Harris T.K.;
RT   "Role of the PH domain in regulating in vitro autophosphorylation
RT   events required for reconstitution of PDK1 catalytic activity.";
RL   Bioorg. Chem. 34:200-223(2006).
RN   [30]
RP   FUNCTION, AND INTERACTION WITH SMAD2; SMAD3; SMAD4 AND SMAD7.
RX   PubMed=17327236; DOI=10.1074/jbc.M609279200;
RA   Seong H.A., Jung H., Kim K.T., Ha H.;
RT   "3-Phosphoinositide-dependent PDK1 negatively regulates transforming
RT   growth factor-beta-induced signaling in a kinase-dependent manner
RT   through physical interaction with Smad proteins.";
RL   J. Biol. Chem. 282:12272-12289(2007).
RN   [31]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=17371830; DOI=10.1083/jcb.200607053;
RA   Primo L., di Blasio L., Roca C., Droetto S., Piva R., Schaffhausen B.,
RA   Bussolino F.;
RT   "Essential role of PDK1 in regulating endothelial cell migration.";
RL   J. Cell Biol. 176:1035-1047(2007).
RN   [32]
RP   FUNCTION IN PHOSPHORYLATION OF PKN2.
RX   PubMed=18835241; DOI=10.1016/j.abb.2008.09.008;
RA   Lim W.G., Chen X., Liu J.P., Tan B.J., Zhou S., Smith A., Lees N.,
RA   Hou L., Gu F., Yu X.Y., Du Y., Smith D., Verma C., Liu K., Duan W.;
RT   "The C-terminus of PRK2/PKNgamma is required for optimal activation by
RT   RhoA in a GTP-dependent manner.";
RL   Arch. Biochem. Biophys. 479:170-178(2008).
RN   [33]
RP   INTERACTION WITH NPRL2, AND ENZYME REGULATION.
RX   PubMed=18616680; DOI=10.1111/j.1349-7006.2008.00874.x;
RA   Kurata A., Katayama R., Watanabe T., Tsuruo T., Fujita N.;
RT   "TUSC4/NPRL2, a novel PDK1-interacting protein, inhibits PDK1 tyrosine
RT   phosphorylation and its downstream signaling.";
RL   Cancer Sci. 99:1827-1834(2008).
RN   [34]
RP   REVIEW ON FUNCTION.
RX   PubMed=18802401; DOI=10.4161/cc.7.19.6810;
RA   Bayascas J.R.;
RT   "Dissecting the role of the 3-phosphoinositide-dependent protein
RT   kinase-1 (PDK1) signalling pathways.";
RL   Cell Cycle 7:2978-2982(2008).
RN   [35]
RP   INTERACTION WITH SRC; RASA1 AND CRK, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=18024423; DOI=10.1074/jbc.M706361200;
RA   Yang K.J., Shin S., Piao L., Shin E., Li Y., Park K.A., Byun H.S.,
RA   Won M., Hong J., Kweon G.R., Hur G.M., Seok J.H., Chun T.,
RA   Brazil D.P., Hemmings B.A., Park J.;
RT   "Regulation of 3-phosphoinositide-dependent protein kinase-1 (PDK1) by
RT   Src involves tyrosine phosphorylation of PDK1 and Src homology 2
RT   domain binding.";
RL   J. Biol. Chem. 283:1480-1491(2008).
RN   [36]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PTPN6.
RX   PubMed=19591923; DOI=10.1016/j.cellsig.2009.06.010;
RA   Sephton C.F., Zhang D., Lehmann T.M., Pennington P.R., Scheid M.P.,
RA   Mousseau D.D.;
RT   "The nuclear localization of 3'-phosphoinositide-dependent kinase-1 is
RT   dependent on its association with the protein tyrosine phosphatase
RT   SHP-1.";
RL   Cell. Signal. 21:1634-1644(2009).
RN   [37]
RP   SUBCELLULAR LOCATION.
RX   PubMed=19276999; DOI=10.1097/WNR.0b013e328329a41a;
RA   Alajajian B.B., Fletcher L., Isgor E., Jimenez D.F., Digicaylioglu M.;
RT   "IGF-I regulated phosphorylation and translocation of PDK-1 in
RT   neurons.";
RL   NeuroReport 20:579-583(2009).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [39]
RP   PHOSPHORYLATION AT THR-354 BY MELK, PHOSPHORYLATION AT SER-394 AND
RP   SER-398 BY MAP3K5, AND MUTAGENESIS OF THR-354; SER-394 AND SER-398.
RX   PubMed=22544756; DOI=10.1074/jbc.M111.331827;
RA   Seong H.A., Jung H., Manoharan R., Ha H.;
RT   "PDK1 phosphorylation at Thr354 by murine protein serine/threonine
RT   kinase 38 contributes to the negative regulation of PDK1 activity.";
RL   J. Biol. Chem. 287:20811-20822(2012).
RN   [40]
RP   UBIQUITINATION, AND DEUBIQUITINATION BY USP4.
RX   PubMed=22347420; DOI=10.1371/journal.pone.0031003;
RA   Uras I.Z., List T., Nijman S.M.;
RT   "Ubiquitin-specific protease 4 inhibits mono-ubiquitination of the
RT   master growth factor signaling kinase PDK1.";
RL   PLoS ONE 7:E31003-E31003(2012).
RN   [41]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 71-359 IN COMPLEX WITH ATP.
RX   PubMed=12169624; DOI=10.1093/emboj/cdf437;
RA   Biondi R.M., Komander D., Thomas C.C., Lizcano J.M., Deak M.,
RA   Alessi D.R., van Aalten D.M.;
RT   "High resolution crystal structure of the human PDK1 catalytic domain
RT   defines the regulatory phosphopeptide docking site.";
RL   EMBO J. 21:4219-4228(2002).
RN   [43]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) OF 51-360 IN COMPLEX WITH ATP.
RX   PubMed=15741170; DOI=10.1074/jbc.M500977200;
RA   Komander D., Kular G., Deak M., Alessi D.R., van Aalten D.M.;
RT   "Role of T-loop phosphorylation in PDK1 activation, stability, and
RT   substrate binding.";
RL   J. Biol. Chem. 280:18797-18802(2005).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.17 ANGSTROMS) OF 74-359, AND PHOSPHORYLATION
RP   AT SER-241.
RX   PubMed=15772071; DOI=10.1074/jbc.M501367200;
RA   Feldman R.I., Wu J.M., Polokoff M.A., Kochanny M.J., Dinter H.,
RA   Zhu D., Biroc S.L., Alicke B., Bryant J., Yuan S., Buckman B.O.,
RA   Lentz D., Ferrer M., Whitlow M., Adler M., Finster S., Chang Z.,
RA   Arnaiz D.O.;
RT   "Novel small molecule inhibitors of 3-phosphoinositide-dependent
RT   kinase-1.";
RL   J. Biol. Chem. 280:19867-19874(2005).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 409-556, SUBUNIT, ENZYME
RP   REGULATION, AND MUTAGENESIS OF THR-513.
RX   PubMed=20978239; DOI=10.1126/scisignal.2000738;
RA   Masters T.A., Calleja V., Armoogum D.A., Marsh R.J., Applebee C.J.,
RA   Laguerre M., Bain A.J., Larijani B.;
RT   "Regulation of 3-phosphoinositide-dependent protein kinase 1 activity
RT   by homodimerization in live cells.";
RL   Sci. Signal. 3:RA78-RA78(2010).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (1.43 ANGSTROMS) OF 51-359 IN COMPLEX WITH ATP,
RP   AND DOMAIN.
RX   PubMed=22999883; DOI=10.1016/j.chembiol.2012.07.017;
RA   Busschots K., Lopez-Garcia L.A., Lammi C., Stroba A., Zeuzem S.,
RA   Piiper A., Alzari P.M., Neimanis S., Arencibia J.M., Engel M.,
RA   Schulze J.O., Biondi R.M.;
RT   "Substrate-selective inhibition of protein kinase PDK1 by small
RT   compounds that bind to the PIF-pocket allosteric docking site.";
RL   Chem. Biol. 19:1152-1163(2012).
CC   -!- FUNCTION: Serine/threonine kinase which acts as a master kinase,
CC       phosphorylating and activating a subgroup of the AGC family of
CC       protein kinases. Its targets include: protein kinase B (PKB/AKT1,
CC       PKB/AKT2, PKB/AKT3), p70 ribosomal protein S6 kinase (RPS6KB1),
CC       p90 ribosomal protein S6 kinase (RPS6KA1, RPS6KA2 and RPS6KA3),
CC       cyclic AMP-dependent protein kinase (PRKACA), protein kinase C
CC       (PRKCD and PRKCZ), serum and glucocorticoid-inducible kinase
CC       (SGK1, SGK2 and SGK3), p21-activated kinase-1 (PAK1), protein
CC       kinase PKN (PKN1 and PKN2). Plays a central role in the
CC       transduction of signals from insulin by providing the activating
CC       phosphorylation to PKB/AKT1, thus propagating the signal to
CC       downstream targets controlling cell proliferation and survival, as
CC       well as glucose and amino acid uptake and storage. Negatively
CC       regulates the TGF-beta-induced signaling by: modulating the
CC       association of SMAD3 and SMAD7 with TGF-beta receptor,
CC       phosphorylating SMAD2, SMAD3, SMAD4 and SMAD7, preventing the
CC       nuclear translocation of SMAD3 and SMAD4 and the translocation of
CC       SMAD7 from the nucleus to the cytoplasm in response to TGF-beta.
CC       Activates PPARG transcriptional activity and promotes adipocyte
CC       differentiation. Activates the NF-kappa-B pathway via
CC       phosphorylation of IKKB. The tyrosine phosphorylated form is
CC       crucial for the regulation of focal adhesions by angiotensin II.
CC       Controls proliferation, survival, and growth of developing
CC       pancreatic cells. Participates in the regulation of Ca(2+) entry
CC       and Ca(2+)-activated K(+) channels of mast cells. Essential for
CC       the motility of vascular endothelial cells (ECs) and is involved
CC       in the regulation of their chemotaxis. Plays a critical role in
CC       cardiac homeostasis by serving as a dual effector for cell
CC       survival and beta-adrenergic response. Plays an important role
CC       during thymocyte development by regulating the expression of key
CC       nutrient receptors on the surface of pre-T cells and mediating
CC       Notch-induced cell growth and proliferative responses. Provides
CC       negative feedback inhibition to toll-like receptor-mediated NF-
CC       kappa-B activation in macrophages. Isoform 3 is catalytically
CC       inactive. {ECO:0000269|PubMed:10226025,
CC       ECO:0000269|PubMed:10480933, ECO:0000269|PubMed:10995762,
CC       ECO:0000269|PubMed:12167717, ECO:0000269|PubMed:14585963,
CC       ECO:0000269|PubMed:14604990, ECO:0000269|PubMed:16207722,
CC       ECO:0000269|PubMed:16251192, ECO:0000269|PubMed:17327236,
CC       ECO:0000269|PubMed:17371830, ECO:0000269|PubMed:18835241,
CC       ECO:0000269|PubMed:9094314, ECO:0000269|PubMed:9445476,
CC       ECO:0000269|PubMed:9707564, ECO:0000269|PubMed:9768361}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Homodimerization regulates its activity by
CC       maintaining the kinase in an autoinhibitory conformation. NPRL2
CC       down-regulates its activity by interfering with tyrosine
CC       phosphorylation at the Tyr-9, Tyr-373 and Tyr-376 residues. The
CC       14-3-3 protein YWHAQ acts as a negative regulator by association
CC       with the residues surrounding the Ser-241 residue. STRAP
CC       positively regulates its activity by enhancing its
CC       autophosphorylation and by stimulating its dissociation from
CC       YWHAQ. SMAD2, SMAD3, SMAD4 and SMAD7 also positively regulate its
CC       activity by stimulating its dissociation from YWHAQ. Activated by
CC       phosphorylation on Tyr-9, Tyr-373 and Tyr-376 by INSR in response
CC       to insulin. {ECO:0000269|PubMed:12177059,
CC       ECO:0000269|PubMed:16251192, ECO:0000269|PubMed:18616680,
CC       ECO:0000269|PubMed:20978239}.
CC   -!- SUBUNIT: Homodimer in its autoinhibited state. Active as monomer.
CC       Interacts with NPRL2, PPARG, PAK1, PTK2B, GRB14, PKN1 (via C-
CC       terminus), STRAP and IKKB. The Tyr-9 phosphorylated form interacts
CC       with SRC, RASA1 and CRK (via their SH2 domains). Interacts with
CC       SGK3 in a phosphorylation-dependent manner. The tyrosine-
CC       phosphorylated form interacts with PTPN6. The Ser-241
CC       phosphorylated form interacts with YWHAH and YWHAQ. Binds INSR in
CC       response to insulin. Interacts (via PH domain) with SMAD3, SMAD4
CC       and SMAD7. Interacts with PKN2; the interaction stimulates PDPK1
CC       autophosphorylation, its PI(3,4,5)P3-dependent kinase activity
CC       toward 'Ser-473' of AKT1 but also activates its kinase activity
CC       toward PRKCD and PRKCZ. {ECO:0000269|PubMed:10226025,
CC       ECO:0000269|PubMed:10995762, ECO:0000269|PubMed:12177059,
CC       ECO:0000269|PubMed:14585963, ECO:0000269|PubMed:14604990,
CC       ECO:0000269|PubMed:15210700, ECO:0000269|PubMed:16207722,
CC       ECO:0000269|PubMed:16251192, ECO:0000269|PubMed:16314505,
CC       ECO:0000269|PubMed:17327236, ECO:0000269|PubMed:18024423,
CC       ECO:0000269|PubMed:18616680, ECO:0000269|PubMed:19591923,
CC       ECO:0000269|PubMed:20978239}.
CC   -!- INTERACTION:
CC       P31749:AKT1; NbExp=3; IntAct=EBI-717097, EBI-296087;
CC       Q00005:PPP2R2B; NbExp=8; IntAct=EBI-717097, EBI-1052159;
CC       Q8IUH5:ZDHHC17; NbExp=3; IntAct=EBI-9087775, EBI-524753;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Cell membrane;
CC       Peripheral membrane protein. Cell junction, focal adhesion.
CC       Note=Tyrosine phosphorylation seems to occur only at the cell
CC       membrane. Translocates to the cell membrane following insulin
CC       stimulation by a mechanism that involves binding to GRB14 and
CC       INSR. SRC and HSP90 promote its localization to the cell membrane.
CC       Its nuclear localization is dependent on its association with
CC       PTPN6 and its phosphorylation at Ser-396. Restricted to the
CC       nucleus in neuronal cells while in non-neuronal cells it is found
CC       in the cytoplasm. The Ser-241 phosphorylated form is distributed
CC       along the perinuclear region in neuronal cells while in non-
CC       neuronal cells it is found in both the nucleus and the cytoplasm.
CC       IGF1 transiently increases phosphorylation at Ser-241 of neuronal
CC       PDPK1, resulting in its translocation to other cellular
CC       compartments. The tyrosine-phosphorylated form colocalizes with
CC       PTK2B in focal adhesions after angiotensin II stimulation.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=O15530-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O15530-2; Sequence=VSP_004894;
CC       Name=3;
CC         IsoId=O15530-3; Sequence=VSP_004895;
CC       Name=4;
CC         IsoId=O15530-4; Sequence=VSP_041902;
CC       Name=5;
CC         IsoId=O15530-5; Sequence=VSP_044796;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Appears to be expressed ubiquitously. The Tyr-
CC       9 phosphorylated form is markedly increased in diseased tissue
CC       compared with normal tissue from lung, liver, colon and breast.
CC       {ECO:0000269|PubMed:18024423}.
CC   -!- INDUCTION: Stimulated by insulin, and the oxidants hydrogen
CC       peroxide and peroxovanadate.
CC   -!- DOMAIN: The PH domain plays a pivotal role in the localization and
CC       nuclear import of PDPK1 and is also essential for its
CC       homodimerization.
CC   -!- DOMAIN: The PIF-pocket is a small lobe in the catalytic domain
CC       required by the enzyme for the binding to the hydrophobic motif of
CC       its substrates. It is an allosteric regulatory site that can
CC       accommodate small compounds acting as allosteric inhibitors.
CC       {ECO:0000305|PubMed:22999883}.
CC   -!- PTM: Phosphorylation on Ser-241 in the activation loop is required
CC       for full activity. PDPK1 itself can autophosphorylate Ser-241,
CC       leading to its own activation. Autophosphorylation is inhibited by
CC       the apoptotic C-terminus cleavage product of PKN2 (By similarity).
CC       Tyr-9 phosphorylation is critical for stabilization of both PDPK1
CC       and the PDPK1/SRC complex via HSP90-mediated protection of PDPK1
CC       degradation. Angiotensin II stimulates the tyrosine
CC       phosphorylation of PDPK1 in vascular smooth muscle in a calcium-
CC       and SRC-dependent manner. Phosphorylated on Tyr-9, Tyr-373 and
CC       Tyr-376 by INSR in response to insulin. Palmitate negatively
CC       regulates autophosphorylation at Ser-241 and palmitate-induced
CC       phosphorylation at Ser-529 and Ser-501 by PKC/PRKCQ negatively
CC       regulates its ability to phosphorylate PKB/AKT1. Phosphorylation
CC       at Thr-354 by MELK partially inhibits kinase activity, the
CC       inhibition is cooperatively enhanced by phosphorylation at Ser-394
CC       and Ser-398 by MAP3K5. {ECO:0000250, ECO:0000269|PubMed:10455013,
CC       ECO:0000269|PubMed:11481331, ECO:0000269|PubMed:14585963,
CC       ECO:0000269|PubMed:15743829, ECO:0000269|PubMed:16314505,
CC       ECO:0000269|PubMed:16780920, ECO:0000269|PubMed:22544756,
CC       ECO:0000269|Ref.8}.
CC   -!- PTM: Autophosphorylated; autophosphorylation is inhibited by the
CC       apoptotic C-terminus cleavage product of PKN2. {ECO:0000250}.
CC   -!- PTM: Monoubiquitinated in the kinase domain, deubiquitinated by
CC       USP4.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PDPK1 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD93072.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF017995; AAC51825.1; -; mRNA.
DR   EMBL; Y15056; CAA75341.1; -; mRNA.
DR   EMBL; CR536517; CAG38755.1; -; mRNA.
DR   EMBL; AB209835; BAD93072.1; ALT_INIT; mRNA.
DR   EMBL; AC093525; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC141586; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC006339; AAH06339.2; -; mRNA.
DR   EMBL; BC012103; AAH12103.1; -; mRNA.
DR   EMBL; BC033494; AAH33494.1; -; mRNA.
DR   CCDS; CCDS10472.1; -. [O15530-1]
DR   CCDS; CCDS10473.1; -. [O15530-4]
DR   CCDS; CCDS58411.1; -. [O15530-5]
DR   RefSeq; NP_001248745.1; NM_001261816.1. [O15530-5]
DR   RefSeq; NP_002604.1; NM_002613.4. [O15530-1]
DR   RefSeq; NP_112558.2; NM_031268.5. [O15530-4]
DR   UniGene; Hs.459691; -.
DR   PDB; 1H1W; X-ray; 2.00 A; A=71-359.
DR   PDB; 1OKY; X-ray; 2.30 A; A=51-360.
DR   PDB; 1OKZ; X-ray; 2.51 A; A=51-360.
DR   PDB; 1UU3; X-ray; 1.70 A; A=51-360.
DR   PDB; 1UU7; X-ray; 1.90 A; A=51-360.
DR   PDB; 1UU8; X-ray; 2.50 A; A=51-360.
DR   PDB; 1UU9; X-ray; 1.95 A; A=72-357.
DR   PDB; 1UVR; X-ray; 2.81 A; A=71-359.
DR   PDB; 1W1D; X-ray; 1.50 A; A=409-556.
DR   PDB; 1W1G; X-ray; 1.45 A; A=409-556.
DR   PDB; 1W1H; X-ray; 1.45 A; A/B/C/D=409-556.
DR   PDB; 1Z5M; X-ray; 2.17 A; A=74-359.
DR   PDB; 2BIY; X-ray; 1.95 A; A=51-360.
DR   PDB; 2PE0; X-ray; 2.35 A; A=74-359.
DR   PDB; 2PE1; X-ray; 2.14 A; A=74-359.
DR   PDB; 2PE2; X-ray; 2.13 A; A=74-359.
DR   PDB; 2R7B; X-ray; 2.70 A; A=48-359.
DR   PDB; 2VKI; X-ray; 1.80 A; A=409-556.
DR   PDB; 2XCH; X-ray; 2.00 A; A=51-359.
DR   PDB; 2XCK; X-ray; 2.30 A; A=51-359.
DR   PDB; 3H9O; X-ray; 2.30 A; A=51-359.
DR   PDB; 3HRC; X-ray; 1.91 A; A=50-359.
DR   PDB; 3HRF; X-ray; 1.90 A; A=50-359.
DR   PDB; 3ION; X-ray; 2.40 A; A=48-359.
DR   PDB; 3IOP; X-ray; 2.20 A; A=48-359.
DR   PDB; 3NAX; X-ray; 1.75 A; A=66-362.
DR   PDB; 3NAY; X-ray; 2.60 A; A/B=66-362.
DR   PDB; 3NUN; X-ray; 2.20 A; A=67-358.
DR   PDB; 3NUS; X-ray; 2.75 A; A=73-358.
DR   PDB; 3NUU; X-ray; 1.98 A; A=73-358.
DR   PDB; 3NUY; X-ray; 2.10 A; A=73-358.
DR   PDB; 3ORX; X-ray; 2.20 A; A/B/C/D/E/F/G/H=51-359.
DR   PDB; 3ORZ; X-ray; 2.00 A; A/B/C/D=51-359.
DR   PDB; 3OTU; X-ray; 2.10 A; A=51-359.
DR   PDB; 3PWY; X-ray; 3.50 A; A=51-359.
DR   PDB; 3QC4; X-ray; 1.80 A; A/B=51-359.
DR   PDB; 3QCQ; X-ray; 2.50 A; A=48-359.
DR   PDB; 3QCS; X-ray; 2.49 A; A=48-359.
DR   PDB; 3QCX; X-ray; 2.30 A; A=48-359.
DR   PDB; 3QCY; X-ray; 2.20 A; A=48-359.
DR   PDB; 3QD0; X-ray; 1.99 A; A=48-359.
DR   PDB; 3QD3; X-ray; 2.00 A; A=48-359.
DR   PDB; 3QD4; X-ray; 2.30 A; A=48-359.
DR   PDB; 3RCJ; X-ray; 1.70 A; A=50-359.
DR   PDB; 3RWP; X-ray; 1.92 A; A=51-359.
DR   PDB; 3RWQ; X-ray; 2.55 A; A=51-359.
DR   PDB; 3SC1; X-ray; 2.70 A; A=50-359.
DR   PDB; 4A06; X-ray; 2.00 A; A=50-359.
DR   PDB; 4A07; X-ray; 1.85 A; A=50-359.
DR   PDB; 4AW0; X-ray; 1.43 A; A=51-359.
DR   PDB; 4AW1; X-ray; 1.68 A; A=51-359.
DR   PDB; 4CT1; X-ray; 1.85 A; A=50-359.
DR   PDB; 4CT2; X-ray; 1.25 A; A=50-359.
DR   PDB; 4RQK; X-ray; 1.55 A; A=50-359.
DR   PDB; 4RQV; X-ray; 1.50 A; A=50-359.
DR   PDB; 4RRV; X-ray; 1.41 A; A=50-359.
DR   PDB; 4XX9; X-ray; 1.40 A; A=50-359.
DR   PDB; 5ACK; X-ray; 1.24 A; A=50-359.
DR   PDB; 5HKM; X-ray; 2.10 A; A=51-359.
DR   PDB; 5HNG; X-ray; 3.01 A; A=51-359.
DR   PDB; 5HO7; X-ray; 3.00 A; A=51-359.
DR   PDB; 5HO8; X-ray; 2.70 A; A=51-359.
DR   PDB; 5LVL; X-ray; 1.40 A; A=50-359.
DR   PDB; 5LVM; X-ray; 1.26 A; A=50-359.
DR   PDB; 5LVN; X-ray; 1.38 A; A=50-359.
DR   PDB; 5LVO; X-ray; 1.09 A; A=50-359.
DR   PDB; 5LVP; X-ray; 2.50 A; A/B/C/D=50-359.
DR   PDB; 5MRD; X-ray; 1.41 A; A=50-359.
DR   PDBsum; 1H1W; -.
DR   PDBsum; 1OKY; -.
DR   PDBsum; 1OKZ; -.
DR   PDBsum; 1UU3; -.
DR   PDBsum; 1UU7; -.
DR   PDBsum; 1UU8; -.
DR   PDBsum; 1UU9; -.
DR   PDBsum; 1UVR; -.
DR   PDBsum; 1W1D; -.
DR   PDBsum; 1W1G; -.
DR   PDBsum; 1W1H; -.
DR   PDBsum; 1Z5M; -.
DR   PDBsum; 2BIY; -.
DR   PDBsum; 2PE0; -.
DR   PDBsum; 2PE1; -.
DR   PDBsum; 2PE2; -.
DR   PDBsum; 2R7B; -.
DR   PDBsum; 2VKI; -.
DR   PDBsum; 2XCH; -.
DR   PDBsum; 2XCK; -.
DR   PDBsum; 3H9O; -.
DR   PDBsum; 3HRC; -.
DR   PDBsum; 3HRF; -.
DR   PDBsum; 3ION; -.
DR   PDBsum; 3IOP; -.
DR   PDBsum; 3NAX; -.
DR   PDBsum; 3NAY; -.
DR   PDBsum; 3NUN; -.
DR   PDBsum; 3NUS; -.
DR   PDBsum; 3NUU; -.
DR   PDBsum; 3NUY; -.
DR   PDBsum; 3ORX; -.
DR   PDBsum; 3ORZ; -.
DR   PDBsum; 3OTU; -.
DR   PDBsum; 3PWY; -.
DR   PDBsum; 3QC4; -.
DR   PDBsum; 3QCQ; -.
DR   PDBsum; 3QCS; -.
DR   PDBsum; 3QCX; -.
DR   PDBsum; 3QCY; -.
DR   PDBsum; 3QD0; -.
DR   PDBsum; 3QD3; -.
DR   PDBsum; 3QD4; -.
DR   PDBsum; 3RCJ; -.
DR   PDBsum; 3RWP; -.
DR   PDBsum; 3RWQ; -.
DR   PDBsum; 3SC1; -.
DR   PDBsum; 4A06; -.
DR   PDBsum; 4A07; -.
DR   PDBsum; 4AW0; -.
DR   PDBsum; 4AW1; -.
DR   PDBsum; 4CT1; -.
DR   PDBsum; 4CT2; -.
DR   PDBsum; 4RQK; -.
DR   PDBsum; 4RQV; -.
DR   PDBsum; 4RRV; -.
DR   PDBsum; 4XX9; -.
DR   PDBsum; 5ACK; -.
DR   PDBsum; 5HKM; -.
DR   PDBsum; 5HNG; -.
DR   PDBsum; 5HO7; -.
DR   PDBsum; 5HO8; -.
DR   PDBsum; 5LVL; -.
DR   PDBsum; 5LVM; -.
DR   PDBsum; 5LVN; -.
DR   PDBsum; 5LVO; -.
DR   PDBsum; 5LVP; -.
DR   PDBsum; 5MRD; -.
DR   ProteinModelPortal; O15530; -.
DR   SMR; O15530; -.
DR   BioGrid; 111196; 59.
DR   DIP; DIP-38372N; -.
DR   IntAct; O15530; 53.
DR   MINT; MINT-1371493; -.
DR   STRING; 9606.ENSP00000344220; -.
DR   BindingDB; O15530; -.
DR   ChEMBL; CHEMBL2534; -.
DR   DrugBank; DB07132; 1-{2-OXO-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-5-YL}UREA.
DR   DrugBank; DB07033; 5-HYDROXY-3-[(1R)-1-(1H-PYRROL-2-YL)ETHYL]-2H-INDOL-2-ONE.
DR   DrugBank; DB01933; 7-Hydroxystaurosporine.
DR   DrugBank; DB00482; Celecoxib.
DR   DrugBank; DB04522; Phosphonoserine.
DR   DrugBank; DB03777; Rbt205 Inhibitor.
DR   DrugBank; DB02010; Staurosporine.
DR   GuidetoPHARMACOLOGY; 1519; -.
DR   iPTMnet; O15530; -.
DR   PhosphoSitePlus; O15530; -.
DR   BioMuta; PDPK1; -.
DR   EPD; O15530; -.
DR   MaxQB; O15530; -.
DR   PaxDb; O15530; -.
DR   PeptideAtlas; O15530; -.
DR   PRIDE; O15530; -.
DR   DNASU; 5170; -.
DR   Ensembl; ENST00000268673; ENSP00000268673; ENSG00000140992. [O15530-4]
DR   Ensembl; ENST00000342085; ENSP00000344220; ENSG00000140992. [O15530-1]
DR   Ensembl; ENST00000441549; ENSP00000395357; ENSG00000140992. [O15530-5]
DR   GeneID; 5170; -.
DR   KEGG; hsa:5170; -.
DR   UCSC; uc002cqs.5; human. [O15530-1]
DR   CTD; 5170; -.
DR   DisGeNET; 5170; -.
DR   GeneCards; PDPK1; -.
DR   H-InvDB; HIX0038570; -.
DR   H-InvDB; HIX0038793; -.
DR   HGNC; HGNC:8816; PDPK1.
DR   HPA; CAB004272; -.
DR   HPA; HPA035199; -.
DR   HPA; HPA068961; -.
DR   MIM; 605213; gene.
DR   neXtProt; NX_O15530; -.
DR   OpenTargets; ENSG00000140992; -.
DR   PharmGKB; PA33160; -.
DR   eggNOG; KOG0592; Eukaryota.
DR   eggNOG; ENOG410XRT8; LUCA.
DR   GeneTree; ENSGT00550000074819; -.
DR   HOGENOM; HOG000233026; -.
DR   HOVERGEN; HBG098357; -.
DR   InParanoid; O15530; -.
DR   KO; K06276; -.
DR   OMA; SGNADRW; -.
DR   OrthoDB; EOG091G06CX; -.
DR   PhylomeDB; O15530; -.
DR   TreeFam; TF105423; -.
DR   BRENDA; 2.7.11.1; 2681.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-165158; Activation of AKT2.
DR   Reactome; R-HSA-202424; Downstream TCR signaling.
DR   Reactome; R-HSA-2730905; Role of LAT2/NTAL/LAB on calcium mobilization.
DR   Reactome; R-HSA-2871837; FCERI mediated NF-kB activation.
DR   Reactome; R-HSA-354192; Integrin alphaIIb beta3 signaling.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-389513; CTLA4 inhibitory signaling.
DR   Reactome; R-HSA-392451; G beta:gamma signalling through PI3Kgamma.
DR   Reactome; R-HSA-444257; RSK activation.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   Reactome; R-HSA-5607764; CLEC7A (Dectin-1) signaling.
DR   Reactome; R-HSA-5625740; RHO GTPases activate PKNs.
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; R-HSA-6804757; Regulation of TP53 Degradation.
DR   SABIO-RK; O15530; -.
DR   SignaLink; O15530; -.
DR   SIGNOR; O15530; -.
DR   ChiTaRS; PDPK1; human.
DR   EvolutionaryTrace; O15530; -.
DR   GeneWiki; Phosphoinositide-dependent_kinase-1; -.
DR   GenomeRNAi; 5170; -.
DR   PRO; PR:O15530; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000140992; -.
DR   CleanEx; HS_PDK1; -.
DR   CleanEx; HS_PDPK1; -.
DR   ExpressionAtlas; O15530; baseline and differential.
DR   Genevisible; O15530; HS.
DR   GO; GO:0042995; C:cell projection; IDA:BHF-UCL.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:Ensembl.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005925; C:focal adhesion; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0043204; C:perikaryon; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IEA:Ensembl.
DR   GO; GO:0004676; F:3-phosphoinositide-dependent protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005158; F:insulin receptor binding; IEA:Ensembl.
DR   GO; GO:0016301; F:kinase activity; TAS:Reactome.
DR   GO; GO:0016004; F:phospholipase activator activity; IMP:BHF-UCL.
DR   GO; GO:0043274; F:phospholipase binding; IPI:BHF-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0030036; P:actin cytoskeleton organization; TAS:ProtInc.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IDA:BHF-UCL.
DR   GO; GO:0019722; P:calcium-mediated signaling; IMP:BHF-UCL.
DR   GO; GO:0016477; P:cell migration; IMP:BHF-UCL.
DR   GO; GO:1990416; P:cellular response to brain-derived neurotrophic factor stimulus; IEA:Ensembl.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IMP:BHF-UCL.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IMP:BHF-UCL.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0097191; P:extrinsic apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0038095; P:Fc-epsilon receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0048041; P:focal adhesion assembly; IEA:Ensembl.
DR   GO; GO:0006972; P:hyperosmotic response; IEA:Ensembl.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:MGI.
DR   GO; GO:0010667; P:negative regulation of cardiac muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0006469; P:negative regulation of protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0034122; P:negative regulation of toll-like receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0030512; P:negative regulation of transforming growth factor beta receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; TAS:Reactome.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0090004; P:positive regulation of establishment of protein localization to plasma membrane; IMP:BHF-UCL.
DR   GO; GO:0010518; P:positive regulation of phospholipase activity; IMP:BHF-UCL.
DR   GO; GO:0051281; P:positive regulation of release of sequestered calcium ion into cytosol; IDA:BHF-UCL.
DR   GO; GO:0046777; P:protein autophosphorylation; TAS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0010594; P:regulation of endothelial cell migration; IEA:Ensembl.
DR   GO; GO:0043122; P:regulation of I-kappaB kinase/NF-kappaB signaling; IMP:UniProtKB.
DR   GO; GO:0043304; P:regulation of mast cell degranulation; IEA:Ensembl.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0002223; P:stimulatory C-type lectin receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0031295; P:T cell costimulation; TAS:Reactome.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0003323; P:type B pancreatic cell development; IEA:Ensembl.
DR   CDD; cd01262; PH_PDK1; 1.
DR   Gene3D; 2.30.29.30; -; 1.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR033931; PDK1-typ_PH.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF14593; PH_3; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF50729; SSF50729; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Activator; Alternative splicing;
KW   ATP-binding; Cell junction; Cell membrane; Complete proteome;
KW   Cytoplasm; Direct protein sequencing; Kinase; Membrane;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation.
FT   CHAIN         1    556       3-phosphoinositide-dependent protein
FT                                kinase 1.
FT                                /FTId=PRO_0000086500.
FT   DOMAIN       82    342       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      459    550       PH.
FT   NP_BIND      92     94       ATP. {ECO:0000269|PubMed:12169624,
FT                                ECO:0000269|PubMed:15741170,
FT                                ECO:0000269|PubMed:22999883}.
FT   NP_BIND     160    162       ATP. {ECO:0000269|PubMed:12169624,
FT                                ECO:0000269|PubMed:15741170,
FT                                ECO:0000269|PubMed:22999883}.
FT   REGION      113    157       PIF-pocket.
FT                                {ECO:0000305|PubMed:22999883}.
FT   COMPBIAS    389    398       Poly-Ser.
FT   ACT_SITE    205    205       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     111    111       ATP. {ECO:0000269|PubMed:12169624,
FT                                ECO:0000269|PubMed:15741170,
FT                                ECO:0000269|PubMed:22999883}.
FT   BINDING     166    166       ATP. {ECO:0000269|PubMed:12169624,
FT                                ECO:0000269|PubMed:15741170,
FT                                ECO:0000269|PubMed:22999883}.
FT   BINDING     209    209       ATP; via carbonyl oxygen.
FT                                {ECO:0000269|PubMed:22999883}.
FT   BINDING     223    223       ATP. {ECO:0000269|PubMed:12169624,
FT                                ECO:0000269|PubMed:15741170,
FT                                ECO:0000269|PubMed:22999883}.
FT   MOD_RES       9      9       Phosphotyrosine; by SRC and INSR.
FT                                {ECO:0000269|PubMed:11481331,
FT                                ECO:0000269|PubMed:14585963,
FT                                ECO:0000269|PubMed:16314505}.
FT   MOD_RES      25     25       Phosphoserine.
FT                                {ECO:0000269|PubMed:10455013}.
FT   MOD_RES     241    241       Phosphoserine; by autocatalysis.
FT                                {ECO:0000269|PubMed:10455013,
FT                                ECO:0000269|PubMed:11481331,
FT                                ECO:0000269|PubMed:15772071,
FT                                ECO:0000269|PubMed:16780920,
FT                                ECO:0000269|Ref.8}.
FT   MOD_RES     304    304       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q9Z2A0}.
FT   MOD_RES     354    354       Phosphothreonine; by MELK.
FT                                {ECO:0000269|PubMed:22544756}.
FT   MOD_RES     373    373       Phosphotyrosine; by SRC and INSR.
FT                                {ECO:0000269|PubMed:11481331,
FT                                ECO:0000269|PubMed:14585963,
FT                                ECO:0000269|PubMed:16314505}.
FT   MOD_RES     376    376       Phosphotyrosine; by SRC and INSR.
FT                                {ECO:0000269|PubMed:11481331,
FT                                ECO:0000269|PubMed:14585963,
FT                                ECO:0000269|PubMed:16314505}.
FT   MOD_RES     393    393       Phosphoserine.
FT                                {ECO:0000269|PubMed:10455013}.
FT   MOD_RES     394    394       Phosphoserine; by MAP3K5.
FT                                {ECO:0000269|PubMed:22544756}.
FT   MOD_RES     396    396       Phosphoserine.
FT                                {ECO:0000269|PubMed:10455013,
FT                                ECO:0000269|PubMed:15743829}.
FT   MOD_RES     398    398       Phosphoserine; by MAP3K5.
FT                                {ECO:0000269|PubMed:22544756}.
FT   MOD_RES     410    410       Phosphoserine.
FT                                {ECO:0000269|PubMed:10455013}.
FT   MOD_RES     501    501       Phosphoserine; by PKC/PRKCQ.
FT                                {ECO:0000250}.
FT   MOD_RES     513    513       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000269|PubMed:16780920}.
FT   MOD_RES     529    529       Phosphoserine; by PKC/PRKCQ.
FT                                {ECO:0000250}.
FT   VAR_SEQ       1     50       Missing (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_004894.
FT   VAR_SEQ     110    237       IKILEKRHIIKENKVPYVTRERDVMSRLDHPFFVKLYFTFQ
FT                                DDEKLYFGLSYAKNGELLKYIRKIGSFDETCTRFYTAEIVS
FT                                ALEYLHGKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSP
FT                                ESKQA -> T (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_041902.
FT   VAR_SEQ     238    263       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:9445477}.
FT                                /FTId=VSP_004895.
FT   VAR_SEQ     448    556       WHQFVENNLILKMGPVDKRKGLFARRRQLLLTEGPHLYYVD
FT                                PVNKVLKGEIPWSQELRPEAKNFKTFFVHTPNRTYYLMDPS
FT                                GNAHKWCRKIQEVWRQRYQSHPDAAVQ -> CLTGRII
FT                                (in isoform 5). {ECO:0000303|Ref.5}.
FT                                /FTId=VSP_044796.
FT   MUTAGEN       9      9       Y->F: Slight reduction in pervanadate-
FT                                stimulated tyrosine phosphorylation.
FT                                {ECO:0000269|PubMed:11481331}.
FT   MUTAGEN      25     25       S->A: No effect.
FT                                {ECO:0000269|PubMed:10455013}.
FT   MUTAGEN     241    241       S->A: No activation.
FT                                {ECO:0000269|PubMed:10455013}.
FT   MUTAGEN     277    277       A->V: 3-fold increase in kinase activity.
FT                                {ECO:0000269|PubMed:10364160}.
FT   MUTAGEN     354    354       T->A: Abolishes phosphorylation by MELK.
FT                                {ECO:0000269|PubMed:22544756}.
FT   MUTAGEN     373    373       Y->F: Reduction in basal activity.
FT                                {ECO:0000269|PubMed:11481331}.
FT   MUTAGEN     376    376       Y->F: Reduction in basal activity.
FT                                {ECO:0000269|PubMed:11481331}.
FT   MUTAGEN     393    393       S->A: No effect.
FT                                {ECO:0000269|PubMed:10455013}.
FT   MUTAGEN     394    394       S->A: Abolishes phosphorylation by
FT                                MAP3K5; when associated with A-398.
FT                                {ECO:0000269|PubMed:22544756}.
FT   MUTAGEN     396    396       S->A: No effect.
FT                                {ECO:0000269|PubMed:10455013}.
FT   MUTAGEN     398    398       S->A: Abolishes phosphorylation by
FT                                MAP3K5; when associated with A-394.
FT                                {ECO:0000269|PubMed:22544756}.
FT   MUTAGEN     410    410       S->A: No effect.
FT                                {ECO:0000269|PubMed:10455013}.
FT   MUTAGEN     474    474       R->A: No PDGF-dependent translocation to
FT                                the membrane.
FT                                {ECO:0000269|PubMed:9637919}.
FT   MUTAGEN     513    513       T->E: Enhanced kinase activity towards
FT                                PKB. {ECO:0000269|PubMed:20978239}.
FT   HELIX        79     81       {ECO:0000244|PDB:5LVO}.
FT   STRAND       82     90       {ECO:0000244|PDB:5LVO}.
FT   STRAND       95    101       {ECO:0000244|PDB:5LVO}.
FT   TURN        102    104       {ECO:0000244|PDB:5LVO}.
FT   STRAND      107    114       {ECO:0000244|PDB:5LVO}.
FT   HELIX       115    120       {ECO:0000244|PDB:5LVO}.
FT   HELIX       124    136       {ECO:0000244|PDB:5LVO}.
FT   STRAND      145    150       {ECO:0000244|PDB:5LVO}.
FT   STRAND      152    159       {ECO:0000244|PDB:5LVO}.
FT   STRAND      163    166       {ECO:0000244|PDB:3PWY}.
FT   HELIX       167    174       {ECO:0000244|PDB:5LVO}.
FT   HELIX       179    198       {ECO:0000244|PDB:5LVO}.
FT   HELIX       208    210       {ECO:0000244|PDB:5LVO}.
FT   STRAND      211    213       {ECO:0000244|PDB:5LVO}.
FT   STRAND      219    221       {ECO:0000244|PDB:5LVO}.
FT   HELIX       224    226       {ECO:0000244|PDB:3ORX}.
FT   TURN        232    235       {ECO:0000244|PDB:5LVO}.
FT   STRAND      238    240       {ECO:0000244|PDB:3OTU}.
FT   HELIX       246    248       {ECO:0000244|PDB:5LVO}.
FT   HELIX       251    256       {ECO:0000244|PDB:5LVO}.
FT   HELIX       261    277       {ECO:0000244|PDB:5LVO}.
FT   HELIX       287    295       {ECO:0000244|PDB:5LVO}.
FT   STRAND      303    305       {ECO:0000244|PDB:3QD3}.
FT   HELIX       307    316       {ECO:0000244|PDB:5LVO}.
FT   HELIX       321    323       {ECO:0000244|PDB:5LVO}.
FT   HELIX       328    330       {ECO:0000244|PDB:5LVO}.
FT   HELIX       333    337       {ECO:0000244|PDB:5LVO}.
FT   HELIX       340    342       {ECO:0000244|PDB:5LVO}.
FT   HELIX       347    352       {ECO:0000244|PDB:5LVO}.
FT   HELIX       412    415       {ECO:0000244|PDB:1W1G}.
FT   STRAND      416    420       {ECO:0000244|PDB:1W1G}.
FT   STRAND      423    426       {ECO:0000244|PDB:1W1G}.
FT   HELIX       432    445       {ECO:0000244|PDB:1W1G}.
FT   HELIX       449    451       {ECO:0000244|PDB:1W1G}.
FT   TURN        452    454       {ECO:0000244|PDB:1W1G}.
FT   STRAND      457    467       {ECO:0000244|PDB:1W1G}.
FT   STRAND      470    479       {ECO:0000244|PDB:1W1G}.
FT   TURN        480    482       {ECO:0000244|PDB:1W1G}.
FT   STRAND      483    488       {ECO:0000244|PDB:1W1G}.
FT   TURN        489    492       {ECO:0000244|PDB:1W1G}.
FT   STRAND      493    498       {ECO:0000244|PDB:1W1G}.
FT   STRAND      505    518       {ECO:0000244|PDB:1W1G}.
FT   STRAND      521    526       {ECO:0000244|PDB:1W1G}.
FT   HELIX       532    547       {ECO:0000244|PDB:1W1G}.
SQ   SEQUENCE   556 AA;  63152 MW;  ED8C0306DC4D0653 CRC64;
     MARTTSQLYD AVPIQSSVVL CSCPSPSMVR TQTESSTPPG IPGGSRQGPA MDGTAAEPRP
     GAGSLQHAQP PPQPRKKRPE DFKFGKILGE GSFSTVVLAR ELATSREYAI KILEKRHIIK
     ENKVPYVTRE RDVMSRLDHP FFVKLYFTFQ DDEKLYFGLS YAKNGELLKY IRKIGSFDET
     CTRFYTAEIV SALEYLHGKG IIHRDLKPEN ILLNEDMHIQ ITDFGTAKVL SPESKQARAN
     SFVGTAQYVS PELLTEKSAC KSSDLWALGC IIYQLVAGLP PFRAGNEYLI FQKIIKLEYD
     FPEKFFPKAR DLVEKLLVLD ATKRLGCEEM EGYGPLKAHP FFESVTWENL HQQTPPKLTA
     YLPAMSEDDE DCYGNYDNLL SQFGCMQVSS SSSSHSLSAS DTGLPQRSGS NIEQYIHDLD
     SNSFELDLQF SEDEKRLLLE KQAGGNPWHQ FVENNLILKM GPVDKRKGLF ARRRQLLLTE
     GPHLYYVDPV NKVLKGEIPW SQELRPEAKN FKTFFVHTPN RTYYLMDPSG NAHKWCRKIQ
     EVWRQRYQSH PDAAVQ
//
